CD46 targeted
212Pb
CD46 epitope
Human monoclonal antibody
Prostate cancer
Prostate cancer patient-derived xenograft model
Radioimmunotherapy
Targeted alpha therapy
mCRPC
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
11 Mar 2023
11 Mar 2023
Historique:
received:
29
12
2022
accepted:
01
03
2023
entrez:
11
3
2023
pubmed:
13
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and developed a microtubule inhibitor-based antibody drug conjugate that is in a multi-center phase I trial for mCRPC (NCT03575819). Here we report the development of a novel CD46-targeted alpha therapy based on YS5. We conjugated
Identifiants
pubmed: 36906664
doi: 10.1186/s13046-023-02636-x
pii: 10.1186/s13046-023-02636-x
pmc: PMC10007843
doi:
Substances chimiques
Lead
2P299V784P
Lead Radioisotopes
0
CD46 protein, human
0
Membrane Cofactor Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Subventions
Organisme : NCI NIH HHS
ID : R01CA223767
Pays : United States
Organisme : NCI NIH HHS
ID : CCSG P30 CA44579
Pays : United States
Organisme : National Institute of Health
ID : S10OD021672
Informations de copyright
© 2023. The Author(s).
Références
Nucl Med Biol. 2021 Jul-Aug;98-99:30-39
pubmed: 34020337
Pharmaceutics. 2021 May 14;13(5):
pubmed: 34069003
J Nucl Med. 2022 Sep;63(9):1326-1333
pubmed: 34992153
Curr Protoc Pharmacol. 2010 Dec;Chapter 14:Unit 14.15
pubmed: 21483646
Top Magn Reson Imaging. 2016 Oct;25(5):237-243
pubmed: 27748709
J Nucl Med. 2023 Jan;64(1):173-176
pubmed: 35798556
Appl Radiat Isot. 2017 Sep;127:52-60
pubmed: 28521118
Mol Pharm. 2019 Apr 1;16(4):1694-1702
pubmed: 30763112
Mol Cell Proteomics. 2006 Dec;5(12):2364-73
pubmed: 16982673
Cancer Res. 2018 Apr 1;78(7):1820-1832
pubmed: 29363548
JCI Insight. 2018 Sep 6;3(17):
pubmed: 30185663
Int J Mol Sci. 2021 May 01;22(9):
pubmed: 34062920
Mol Diagn Ther. 2022 Jul;26(4):467-475
pubmed: 35553387
Semin Nucl Med. 2019 Jul;49(4):302-312
pubmed: 31227053
Nucl Med Biol. 2017 Aug;51:1-9
pubmed: 28486098
Methods Mol Biol. 2018;1701:331-347
pubmed: 29116514
Cancer Biother Radiopharm. 2014 Feb;29(1):12-7
pubmed: 24229395
Appl Radiat Isot. 2020 Dec;166:109362
pubmed: 32979756
Transl Oncol. 2017 Aug;10(4):535-545
pubmed: 28577439
Am J Clin Oncol. 2018 Jul;41(7):716-721
pubmed: 27906723
Int J Mol Sci. 2018 Mar 21;19(4):
pubmed: 29561763
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
J Clin Invest. 2016 Dec 1;126(12):4640-4653
pubmed: 27841764
Nuklearmedizin. 2020 Feb;59(1):33-34
pubmed: 31766065
Int J Oncol. 2012 Jun;40(6):1881-8
pubmed: 22322558
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
EJNMMI Radiopharm Chem. 2021 Feb 1;6(1):6
pubmed: 33527221
Clin Cancer Res. 2021 Mar 1;27(5):1305-1315
pubmed: 33293372
J Nucl Med. 2010 Mar;51(3):427-32
pubmed: 20150269
Cancers (Basel). 2018 Nov 13;10(11):
pubmed: 30428629
Nucl Med Biol. 2013 Jul;40(5):592-9
pubmed: 23602604
Pharmaceutics. 2022 Jan 13;14(1):
pubmed: 35057083
Br J Cancer. 2021 Dec;125(12):1657-1665
pubmed: 34671126
Mol Imaging. 2011 Apr;10(2):111-22
pubmed: 21439256
Pathol Oncol Res. 2009 Jun;15(2):167-72
pubmed: 18802790
PLoS One. 2020 Mar 18;15(3):e0230526
pubmed: 32187209
J Nucl Med. 2020 Jan;61(1):80-88
pubmed: 31253744